プロの翻訳者、企業、ウェブページから自由に利用できる翻訳レポジトリまで。
Í langtímaframhaldshluta rannsóknaráætlunar 018 var fylgst með 369 stúlkum sem bólusettar voru með silgard á aldrinum 9–15 ára í grunnrannsókninni.
in the long-term extension study of protocol 018, 369 girls 9-15 years old during vaccination with silgard in the base study, were followed.
engin marktækur munur á heildarlifun kom fram á milli meðferðarhópanna tveggja við lokagreiningu á heildarlifun eftir að 76% tilvika höfðu komið fram (280/369) (áhættuhlutfall 0,97, 95% ci 0,67, 1,12 p=0,256).
no significant difference in os was observed between the two treatment arms at the final os analysis performed after 76% (280/369) of the events had occurred (hr 0.87, 95% ci 0.67, 1.12 p=0.256).